Forskolin  ||| S:0 E:10 ||| NNP
and  ||| S:10 E:14 ||| CC
rutin  ||| S:14 E:20 ||| RB
prevent  ||| S:20 E:28 ||| VB
intraocular  ||| S:28 E:40 ||| JJ
pressure  ||| S:40 E:49 ||| NN
spikes  ||| S:49 E:56 ||| NN
after  ||| S:56 E:62 ||| IN
Nd ||| S:62 E:64 ||| NNP
: ||| S:64 E:65 ||| :
YAG  ||| S:65 E:69 ||| NNP
laser  ||| S:69 E:75 ||| NN
iridotomy  ||| S:75 E:85 ||| VBD
the  ||| S:85 E:89 ||| DT
purpose  ||| S:89 E:97 ||| NN
of  ||| S:97 E:100 ||| IN
this  ||| S:100 E:105 ||| DT
research  ||| S:105 E:114 ||| NN
was  ||| S:114 E:118 ||| VBD
to  ||| S:118 E:121 ||| TO
evaluate  ||| S:121 E:130 ||| VB
whether  ||| S:130 E:138 ||| IN
an  ||| S:138 E:141 ||| DT
oral  ||| S:141 E:146 ||| JJ
treatment  ||| S:146 E:156 ||| NN
with  ||| S:156 E:161 ||| IN
an  ||| S:161 E:164 ||| DT
association  ||| S:164 E:176 ||| NN
of  ||| S:176 E:179 ||| IN
forskolin  ||| S:179 E:189 ||| NN
and  ||| S:189 E:193 ||| CC
rutin  ||| S:193 E:199 ||| NNS
can  ||| S:199 E:203 ||| MD
blunt  ||| S:203 E:209 ||| VB
the  ||| S:209 E:213 ||| DT
intraocular  ||| S:213 E:225 ||| JJ
pressure  ||| S:225 E:234 ||| NN
( ||| S:234 E:235 ||| -LRB-
IOP ||| S:235 E:238 ||| NNP
)  ||| S:238 E:240 ||| -RRB-
spikes  ||| S:240 E:247 ||| NN
and  ||| S:247 E:251 ||| CC
avoid  ||| S:251 E:257 ||| VB
the  ||| S:257 E:261 ||| DT
damage  ||| S:261 E:268 ||| NN
that  ||| S:268 E:273 ||| WDT
may  ||| S:273 E:277 ||| MD
occur  ||| S:277 E:283 ||| VB
after  ||| S:283 E:289 ||| IN
laser  ||| S:289 E:295 ||| NN
iridotomy ||| S:295 E:304 ||| NN
.  ||| S:304 E:306 ||| .
Ten  ||| S:306 E:310 ||| CD
patients  ||| S:310 E:319 ||| NNS
underwent  ||| S:319 E:329 ||| VBD
bilateral  ||| S:329 E:339 ||| JJ
Neodymium ||| S:339 E:348 ||| NNP
: ||| S:348 E:349 ||| :
YAG  ||| S:349 E:353 ||| NNP
( ||| S:353 E:354 ||| -LRB-
Nd ||| S:354 E:356 ||| NNP
: ||| S:356 E:357 ||| :
YAG ||| S:357 E:360 ||| NNP
)  ||| S:360 E:362 ||| -RRB-
laser  ||| S:362 E:368 ||| NN
iridotomy  ||| S:368 E:378 ||| NNS
( ||| S:378 E:379 ||| -LRB-
Visulas  ||| S:379 E:387 ||| NNP
YAG  ||| S:387 E:391 ||| NNP
III  ||| S:391 E:395 ||| NNP
Laser ||| S:395 E:400 ||| NNP
,  ||| S:400 E:402 ||| ,
Zeiss ||| S:402 E:407 ||| NNP
) ||| S:407 E:408 ||| -RRB-
,  ||| S:408 E:410 ||| ,
for  ||| S:410 E:414 ||| IN
the  ||| S:414 E:418 ||| DT
prevention  ||| S:418 E:429 ||| NN
of  ||| S:429 E:432 ||| IN
primary  ||| S:432 E:440 ||| JJ
closed-angle  ||| S:440 E:453 ||| JJ
glaucoma ||| S:453 E:461 ||| NN
.  ||| S:461 E:463 ||| .
IOP  ||| S:463 E:467 ||| NNP
was  ||| S:467 E:471 ||| VBD
measured  ||| S:471 E:480 ||| VBN
in  ||| S:480 E:483 ||| IN
subjects  ||| S:483 E:492 ||| NNS
before  ||| S:492 E:499 ||| IN
and  ||| S:499 E:503 ||| CC
after  ||| S:503 E:509 ||| IN
7  ||| S:509 E:511 ||| CD
days  ||| S:511 E:516 ||| NNS
of  ||| S:516 E:519 ||| IN
pretreatment  ||| S:519 E:532 ||| NN
with  ||| S:532 E:537 ||| IN
placebo  ||| S:537 E:545 ||| NN
or  ||| S:545 E:548 ||| CC
forskolin  ||| S:548 E:558 ||| NNS
and  ||| S:558 E:562 ||| CC
rutin  ||| S:562 E:568 ||| NN
by  ||| S:568 E:571 ||| IN
Goldman  ||| S:571 E:579 ||| NNP
applanation  ||| S:579 E:591 ||| FW
tonometry ||| S:591 E:600 ||| FW
.  ||| S:600 E:602 ||| .
The  ||| S:602 E:606 ||| DT
IOP  ||| S:606 E:610 ||| NNP
was  ||| S:610 E:614 ||| VBD
measured  ||| S:614 E:623 ||| VBN
before  ||| S:623 E:630 ||| IN
surgery  ||| S:630 E:638 ||| NN
and  ||| S:638 E:642 ||| CC
after  ||| S:642 E:648 ||| IN
surgery  ||| S:648 E:656 ||| NN
at  ||| S:656 E:659 ||| IN
30-60-120  ||| S:659 E:669 ||| CD
minutes ||| S:669 E:676 ||| NNS
,  ||| S:676 E:678 ||| ,
and  ||| S:678 E:682 ||| CC
4-7  ||| S:682 E:686 ||| CD
days ||| S:686 E:690 ||| NNS
.  ||| S:690 E:692 ||| .
Analysis  ||| S:692 E:701 ||| NN
of  ||| S:701 E:704 ||| IN
variance  ||| S:704 E:713 ||| NN
indicated  ||| S:713 E:723 ||| VBD
a  ||| S:723 E:725 ||| DT
significant  ||| S:725 E:737 ||| JJ
increase  ||| S:737 E:746 ||| NN
of  ||| S:746 E:749 ||| IN
the  ||| S:749 E:753 ||| DT
postoperative  ||| S:753 E:767 ||| JJ
values  ||| S:767 E:774 ||| NNS
in  ||| S:774 E:777 ||| IN
patients  ||| S:777 E:786 ||| NNS
receiving  ||| S:786 E:796 ||| VBG
treatment  ||| S:796 E:806 ||| NN
with  ||| S:806 E:811 ||| IN
placebo  ||| S:811 E:819 ||| NNS
( ||| S:819 E:820 ||| -LRB-
p  ||| S:820 E:822 ||| FW
< ||| S:822 E:824 ||| SYM
0.001 ||| S:824 E:829 ||| FW
) ||| S:829 E:830 ||| -RRB-
,  ||| S:830 E:832 ||| ,
but  ||| S:832 E:836 ||| CC
not  ||| S:836 E:840 ||| RB
in  ||| S:840 E:843 ||| IN
those  ||| S:843 E:849 ||| DT
who  ||| S:849 E:853 ||| WP
received  ||| S:853 E:862 ||| VBD
treatment  ||| S:862 E:872 ||| NN
with  ||| S:872 E:877 ||| IN
the  ||| S:877 E:881 ||| DT
forskolin  ||| S:881 E:891 ||| NN
and  ||| S:891 E:895 ||| CC
rutin  ||| S:895 E:901 ||| JJ
association ||| S:901 E:912 ||| NN
.  ||| S:912 E:914 ||| .
T  ||| S:914 E:916 ||| NN
test  ||| S:916 E:921 ||| NN
analysis  ||| S:921 E:930 ||| NN
confirmed  ||| S:930 E:940 ||| VBD
that  ||| S:940 E:945 ||| IN
IOP  ||| S:945 E:949 ||| NNP
still  ||| S:949 E:955 ||| RB
remained  ||| S:955 E:964 ||| VBD
significantly  ||| S:964 E:978 ||| RB
elevated  ||| S:978 E:987 ||| VBD
7  ||| S:987 E:989 ||| CD
days  ||| S:989 E:994 ||| NNS
after  ||| S:994 E:1000 ||| IN
laser  ||| S:1000 E:1006 ||| NN
intervention  ||| S:1006 E:1019 ||| NN
in  ||| S:1019 E:1022 ||| IN
placebo  ||| S:1022 E:1030 ||| JJ
treated  ||| S:1030 E:1038 ||| JJ
patients ||| S:1038 E:1046 ||| NNS
,  ||| S:1046 E:1048 ||| ,
whereas  ||| S:1048 E:1056 ||| IN
it  ||| S:1056 E:1059 ||| PRP
stayed  ||| S:1059 E:1066 ||| VBD
within  ||| S:1066 E:1073 ||| IN
normal  ||| S:1073 E:1080 ||| JJ
values  ||| S:1080 E:1087 ||| NNS
in  ||| S:1087 E:1090 ||| IN
forskolin ||| S:1090 E:1099 ||| CD
/ ||| S:1099 E:1100 ||| CD
rutin  ||| S:1100 E:1106 ||| NNS
treated  ||| S:1106 E:1114 ||| VBN
patients ||| S:1114 E:1122 ||| NNS
.  ||| S:1122 E:1124 ||| .
Forskolin  ||| S:1124 E:1134 ||| NNP
and  ||| S:1134 E:1138 ||| CC
rutin  ||| S:1138 E:1144 ||| NNS
can  ||| S:1144 E:1148 ||| MD
blunt  ||| S:1148 E:1154 ||| VB
the  ||| S:1154 E:1158 ||| DT
increase  ||| S:1158 E:1167 ||| NN
of  ||| S:1167 E:1170 ||| IN
IOP  ||| S:1170 E:1174 ||| NNP
that  ||| S:1174 E:1179 ||| WDT
occurs  ||| S:1179 E:1186 ||| VBZ
after  ||| S:1186 E:1192 ||| IN
Nd-YAG  ||| S:1192 E:1199 ||| JJ
laser  ||| S:1199 E:1205 ||| NN
iridotomy ||| S:1205 E:1214 ||| NN
.  ||| S:1214 E:1216 ||| .
This  ||| S:1216 E:1221 ||| DT
can  ||| S:1221 E:1225 ||| MD
avoid  ||| S:1225 E:1231 ||| VB
serious  ||| S:1231 E:1239 ||| JJ
risk  ||| S:1239 E:1244 ||| NN
to  ||| S:1244 E:1247 ||| TO
the  ||| S:1247 E:1251 ||| DT
optic  ||| S:1251 E:1257 ||| JJ
nerve  ||| S:1257 E:1263 ||| NN
of  ||| S:1263 E:1266 ||| IN
the  ||| S:1266 E:1270 ||| DT
patients  ||| S:1270 E:1279 ||| NNS
under  ||| S:1279 E:1285 ||| IN
laser  ||| S:1285 E:1291 ||| NN
treatment  ||| S:1291 E:1301 ||| NN
for  ||| S:1301 E:1305 ||| IN
iridotomy ||| S:1305 E:1314 ||| NN
.  ||| S:1314 E:1316 ||| .
